Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma	Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, primary central nervous system lymphoma	Recruiting	Phase 2	2025-04-23		NCT05209620

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Henan Cancer Hospital	147

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university	Zhengzhou	China	5

Clinical trials